Evidence map›Paper›PMID 31624334›Full record

ArticleThe pharmacogenomics journal2020

Dissecting the m

Qianqian Meng, Shuyuan Wang, Shunheng Zhou, Haizhou Liu, Xueyan Ma, Xu Zhou, Hui Liu, Chaohan Xu, Wei Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Review
  3. FTO in Lung Cancer: Its Progression and Therapeutic Potential.Combinatorial chemistry & high throughput screening · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Emerging role of N6-methyladenosine RNA methylation in lung diseases.Experimental biology and medicine (Maywood, N.J.) · 2022
    Review
  9. Article
  10. Review
  11. Importance of NMolecular and clinical oncology · 2021
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. mFrontiers in genetics · 2021
    Article
  17. Review
  18. RNA mInnovation (Cambridge (Mass.)) · 2020
    Review
  19. [Research Advances of m⁶A RNA Methylation in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Qianqian MengCollege of Bioinformatics Science and Technology, Harbin Medical University, 150081, Harbin, China.
Shuyuan WangCollege of Bioinformatics Science and Technology, Harbin Medical University, 150081, Harbin, China.
Shunheng ZhouCollege of Automation Engineering, Nanjing University of Aeronautics and Astronautics, 211106, Nanjing, China.
Haizhou LiuCollege of Automation Engineering, Nanjing University of Aeronautics and Astronautics, 211106, Nanjing, China.
Xueyan MaCollege of Bioinformatics Science and Technology, Harbin Medical University, 150081, Harbin, China.
Xu ZhouCollege of Bioinformatics Science and Technology, Harbin Medical University, 150081, Harbin, China.
Hui LiuCollege of Bioinformatics Science and Technology, Harbin Medical University, 150081, Harbin, China.
Chaohan XuCollege of Bioinformatics Science and Technology, Harbin Medical University, 150081, Harbin, China. chaohanxu@hrbmu.edu.cn.
Wei JiangCollege of Bioinformatics Science and Technology, Harbin Medical University, 150081, Harbin, China. weijiang@nuaa.edu.cn.
Harbin Medical University · CNNanjing University of Aeronautics and Astronautics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer deaths. Afatinib is the first-line anti-cancer agent for treatment of NSCLC. However, unexpected resistance has been a major obstacle for its clinical efficacy. In this study, we dissected afatinib resistance from the perspective of N

Indexed as

A549 CellsAdenosineAfatinibAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmHumansLung NeoplasmsAdenosineAfatinibAntineoplastic AgentsN-methyladenosine

Identifiers

PMID31624334
OpenAlexW2980588320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.